# pathway_0051: before and after transfer clarification

[All 1,328 cases](../README.md) · [Method](../METHOD.md) · [Summary](../SUMMARY.md) · [Exact reviewer user message](../inputs/pathway_0051.txt)

**Task:** `pathway`  
**Author key, unchanged:** **C** — Cofactor biosynthesis

| Round | Reviewer | Key support | Transfer / lookup | Output usability (canonical status) |
|---|---|---|---|---|
| before | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| before | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |
| after | GPT-6 Luna | supported | reasoning-supported | usable output (valid_review) |
| after | Qwen3.8-Flash-Next-NVFP4 | supported | reasoning-supported | usable output (valid_review) |

**Usable output means format-valid review, not reasoning-supported or biologically correct.** A usable output can classify the question as reasoning-supported, lookup-dependent or uncertain. An output error is a problem with the saved model response; it does not count a defective benchmark question or wrong key. Each saved review is retained in full below. Labels from output errors are displayed as saved and excluded from label statistics. The author key and reviewer evidence were visible to reviewers; this is a review of answerability and key support, not a benchmark-solving score.

## Complete original question

```text
[Protein Sequence]
MMESAVTAHTLRIAMAQFDFPVGAVTQNTDRIIEYIAAARDEFEADIVLFPELAISGYPPEDLLLRPGFLAHCEQALARIAAATRGIVAVVGWPQSAGSVVYNAASVLREGRIEATYRKRELPNYAVFDERRYFDVDPDGDNCVVTVKGVQVGVVICEDLWFAEPLAKTVQAGAELVLVPNASPYERGKHAQRDALLAERTRESGAAIAYLNVVGGQDALVFDGASVVADGDGTVHPAAAAFVDQWLVVDYAAGERSFTPVVWVDDGDESMDALAWRAVVRGLKDYCGKNGFRKVWLGLSGGIDSALVLAMAVDALGGENVTAVRLPSRYTAGLSNDLADEQCRALGVKLETIAIEPAFEGLLAALGPLFADTQPDITEENLQSRSRGVILMALSNKFGGLVLTTGNKSEYAVGYATIYGDMCGGYAPLKDLYKTEVFGLAKWRNTVGGAPVIPPAVISRPPSAELRDNQTDQDSLPPYDVLDGILYRYVDQEQSRDDIVAAGYAADTVEHVLRLVRLNEWKRHQAAPGPKVSRRAFGRERRYPITNGYSGQ

[Multiple Choices]
A. Antifungal biosynthesis. .
B. L-cystathionine from O-succinyl-L-homoserine: step 1/1. .
C. Cofactor biosynthesis
D. Membrane lipid metabolism. .
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Four saved visible reviews

## Before: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches a UniProt entry annotated as glutamine-dependent NAD(+) synthetase, with a pathway annotation placing it in NAD(+) biosynthesis under cofactor biosynthesis. The enzyme annotation and pathway assignment are supported by a computational HAMAP rule; the supplied excerpts do not independently establish an experimental assay of the enzyme's activity.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [H1](#evidence-h1), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence alone does not provide a readily interpretable clue that distinguishes NAD(+) biosynthesis from the listed alternatives without identifying its specific enzyme family and function.


**Missing item-specific fact**

> That this particular sequence is a glutamine-dependent NAD(+) synthetase functioning in NAD(+) biosynthesis.


**Reason**

> Choosing C depends on a protein-specific functional assignment absent from the input. Recognizing the sequence or obtaining its annotation through an external homology or database lookup would not make the question reasoning-supported.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> Given the supported NAD(+) biosynthesis assignment, cofactor biosynthesis is the matching listed category; the other choices do not describe that pathway.


### Important caveats

- The sequence match applies to both the current and retrieved historical UniProt record, but the author's exact source snapshot is unknown.
- The pathway annotation is computationally supported by HAMAP; the cited publication excerpt concerns NAD(+) biosynthesis and a disruption phenotype, not a directly shown enzyme assay.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence alone does not provide a readily interpretable clue that distinguishes NAD(+) biosynthesis from the listed alternatives without identifying its specific enzyme family and function.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "That this particular sequence is a glutamine-dependent NAD(+) synthetase functioning in NAD(+) biosynthesis.",
    "reason": "Choosing C depends on a protein-specific functional assignment absent from the input. Recognizing the sequence or obtaining its annotation through an external homology or database lookup would not make the question reasoning-supported."
  },
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "H1",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches a UniProt entry annotated as glutamine-dependent NAD(+) synthetase, with a pathway annotation placing it in NAD(+) biosynthesis under cofactor biosynthesis. The enzyme annotation and pathway assignment are supported by a computational HAMAP rule; the supplied excerpts do not independently establish an experimental assay of the enzyme's activity."
  },
  "important_caveats": [
    "The sequence match applies to both the current and retrieved historical UniProt record, but the author's exact source snapshot is unknown.",
    "The pathway annotation is computationally supported by HAMAP; the cited publication excerpt concerns NAD(+) biosynthesis and a disruption phenotype, not a directly shown enzyme assay."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "Given the supported NAD(+) biosynthesis assignment, cofactor biosynthesis is the matching listed category; the other choices do not describe that pathway."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches a UniProt entry annotated as glutamine-dependent NAD(+) synthetase, with a pathway annotation placing it in NAD(+) biosynthesis under cofactor biosynthesis. The enzyme annotation and pathway assignment are supported by a computational HAMAP rule; the supplied excerpts do not independently establish an experimental assay of the enzyme's activity.",
    "evidence_ids": ["C1", "C4", "C5", "H1", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence alone does not provide a readily interpretable clue that distinguishes NAD(+) biosynthesis from the listed alternatives without identifying its specific enzyme family and function.",
    "missing_item_specific_fact": "That this particular sequence is a glutamine-dependent NAD(+) synthetase functioning in NAD(+) biosynthesis.",
    "reason": "Choosing C depends on a protein-specific functional assignment absent from the input. Recognizing the sequence or obtaining its annotation through an external homology or database lookup would not make the question reasoning-supported."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "Given the supported NAD(+) biosynthesis assignment, cofactor biosynthesis is the matching listed category; the other choices do not describe that pathway."
  },
  "important_caveats": [
    "The sequence match applies to both the current and retrieved historical UniProt record, but the author's exact source snapshot is unknown.",
    "The pathway annotation is computationally supported by HAMAP; the cited publication excerpt concerns NAD(+) biosynthesis and a disruption phenotype, not a directly shown enzyme assay."
  ]
}
```

</details>

## Before: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence matches UniProt entry A0A0H2X6L3 (NADE_XANC8), annotated as Glutamine-dependent NAD(+) synthetase (EC 6.3.5.1). The UniProt PATHWAY comment explicitly states 'Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1,' directly supporting Choice C. The annotation is based on HAMAP-Rule MF_02090 (ECO:0000255, computational/curated), with additional support from a 2024 disruption phenotype study (PubMed 38429435). The other options (antifungal biosynthesis, cystathionine synthesis, membrane lipid metabolism) are unrelated to NAD+ synthetase.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [H1](#evidence-h1), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The N-terminal region contains a glutaminase domain with a recognizable Cys-His-Asp catalytic triad motif (e.g., 'CEQ' near position 65, conserved 'W' residues in the oxyanion hole region), and the C-terminal region displays a synthetase domain with ATP-binding 'G' motifs. This two-domain glutaminase + synthetase architecture is characteristic of glutamine-dependent amidotransferases, which are predominantly involved in cofactor biosynthesis (NAD+, NADP+, folate, etc.). The other three options are clearly inconsistent: antifungal biosynthesis implies NRPS/PKS features absent here; cystathionine gamma-synthase is a PLP-dependent enzyme with entirely different fold; membrane lipid metabolism enzymes lack this amidotransferase architecture. The broad pathway category 'Cofactor biosynthesis' is reachable from recognizing the glutamine amidotransferase fold without needing the exact enzyme name.


**Missing item-specific fact**

> Precisely distinguishing NAD+ synthetase from other glutamine amidotransferases (e.g., GMP synthetase, folate synthetase) from sequence alone would require specialized fold recognition or database lookup, but the answer category 'Cofactor biosynthesis' is broad enough that the amidotransferase architecture reasoning suffices.


**Reason**

> The glutaminase + synthetase domain architecture is identifiable from sequence motifs and is strongly associated with cofactor biosynthesis. The three distractors describe pathways catalyzed by structurally unrelated enzymes (NRPS/PKS, PLP-dependent synthase, lipid-modifying enzymes), making them eliminable by general biological reasoning. The broad pathway label 'Cofactor biosynthesis' does not require pinpointing the exact enzyme.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The glutaminase + synthetase architecture is incompatible with antifungal biosynthesis (A), cystathionine gamma-synthase (B, PLP-dependent), or membrane lipid metabolism (D). Only 'Cofactor biosynthesis' (C) is consistent with a glutamine-dependent amidotransferase involved in NAD+ biosynthesis. No other option is defensible.


### Important caveats

- The UniProt pathway annotation is based on HAMAP-Rule MF_02090 (ECO:0000255), a computational/curated assignment, not direct enzymatic assay evidence for this specific protein. However, a 2024 disruption phenotype study (PubMed 38429435) provides experimental support for NAD+ biosynthesis function in this organism.
- The reviewer identified the accession from dataset metadata; the evaluated model received only the raw sequence and four pathway labels.
- The pathway annotation is a broad category ('Cofactor biosynthesis'); the full UniProt line specifies the sub-pathway 'NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1,' but the question only asks for the top-level pathway.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The N-terminal region contains a glutaminase domain with a recognizable Cys-His-Asp catalytic triad motif (e.g., 'CEQ' near position 65, conserved 'W' residues in the oxyanion hole region), and the C-terminal region displays a synthetase domain with ATP-binding 'G' motifs. This two-domain glutaminase + synthetase architecture is characteristic of glutamine-dependent amidotransferases, which are predominantly involved in cofactor biosynthesis (NAD+, NADP+, folate, etc.). The other three options are clearly inconsistent: antifungal biosynthesis implies NRPS/PKS features absent here; cystathionine gamma-synthase is a PLP-dependent enzyme with entirely different fold; membrane lipid metabolism enzymes lack this amidotransferase architecture. The broad pathway category 'Cofactor biosynthesis' is reachable from recognizing the glutamine amidotransferase fold without needing the exact enzyme name.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "Precisely distinguishing NAD+ synthetase from other glutamine amidotransferases (e.g., GMP synthetase, folate synthetase) from sequence alone would require specialized fold recognition or database lookup, but the answer category 'Cofactor biosynthesis' is broad enough that the amidotransferase architecture reasoning suffices.",
    "reason": "The glutaminase + synthetase domain architecture is identifiable from sequence motifs and is strongly associated with cofactor biosynthesis. The three distractors describe pathways catalyzed by structurally unrelated enzymes (NRPS/PKS, PLP-dependent synthase, lipid-modifying enzymes), making them eliminable by general biological reasoning. The broad pathway label 'Cofactor biosynthesis' does not require pinpointing the exact enzyme."
  },
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "H1",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence matches UniProt entry A0A0H2X6L3 (NADE_XANC8), annotated as Glutamine-dependent NAD(+) synthetase (EC 6.3.5.1). The UniProt PATHWAY comment explicitly states 'Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1,' directly supporting Choice C. The annotation is based on HAMAP-Rule MF_02090 (ECO:0000255, computational/curated), with additional support from a 2024 disruption phenotype study (PubMed 38429435). The other options (antifungal biosynthesis, cystathionine synthesis, membrane lipid metabolism) are unrelated to NAD+ synthetase."
  },
  "important_caveats": [
    "The UniProt pathway annotation is based on HAMAP-Rule MF_02090 (ECO:0000255), a computational/curated assignment, not direct enzymatic assay evidence for this specific protein. However, a 2024 disruption phenotype study (PubMed 38429435) provides experimental support for NAD+ biosynthesis function in this organism.",
    "The reviewer identified the accession from dataset metadata; the evaluated model received only the raw sequence and four pathway labels.",
    "The pathway annotation is a broad category ('Cofactor biosynthesis'); the full UniProt line specifies the sub-pathway 'NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1,' but the question only asks for the top-level pathway."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The glutaminase + synthetase architecture is incompatible with antifungal biosynthesis (A), cystathionine gamma-synthase (B, PLP-dependent), or membrane lipid metabolism (D). Only 'Cofactor biosynthesis' (C) is consistent with a glutamine-dependent amidotransferase involved in NAD+ biosynthesis. No other option is defensible."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence matches UniProt entry A0A0H2X6L3 (NADE_XANC8), annotated as Glutamine-dependent NAD(+) synthetase (EC 6.3.5.1). The UniProt PATHWAY comment explicitly states 'Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1,' directly supporting Choice C. The annotation is based on HAMAP-Rule MF_02090 (ECO:0000255, computational/curated), with additional support from a 2024 disruption phenotype study (PubMed 38429435). The other options (antifungal biosynthesis, cystathionine synthesis, membrane lipid metabolism) are unrelated to NAD+ synthetase.",
    "evidence_ids": ["C1", "C4", "C5", "H1", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The N-terminal region contains a glutaminase domain with a recognizable Cys-His-Asp catalytic triad motif (e.g., 'CEQ' near position 65, conserved 'W' residues in the oxyanion hole region), and the C-terminal region displays a synthetase domain with ATP-binding 'G' motifs. This two-domain glutaminase + synthetase architecture is characteristic of glutamine-dependent amidotransferases, which are predominantly involved in cofactor biosynthesis (NAD+, NADP+, folate, etc.). The other three options are clearly inconsistent: antifungal biosynthesis implies NRPS/PKS features absent here; cystathionine gamma-synthase is a PLP-dependent enzyme with entirely different fold; membrane lipid metabolism enzymes lack this amidotransferase architecture. The broad pathway category 'Cofactor biosynthesis' is reachable from recognizing the glutamine amidotransferase fold without needing the exact enzyme name.",
    "missing_item_specific_fact": "Precisely distinguishing NAD+ synthetase from other glutamine amidotransferases (e.g., GMP synthetase, folate synthetase) from sequence alone would require specialized fold recognition or database lookup, but the answer category 'Cofactor biosynthesis' is broad enough that the amidotransferase architecture reasoning suffices.",
    "reason": "The glutaminase + synthetase domain architecture is identifiable from sequence motifs and is strongly associated with cofactor biosynthesis. The three distractors describe pathways catalyzed by structurally unrelated enzymes (NRPS/PKS, PLP-dependent synthase, lipid-modifying enzymes), making them eliminable by general biological reasoning. The broad pathway label 'Cofactor biosynthesis' does not require pinpointing the exact enzyme."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The glutaminase + synthetase architecture is incompatible with antifungal biosynthesis (A), cystathionine gamma-synthase (B, PLP-dependent), or membrane lipid metabolism (D). Only 'Cofactor biosynthesis' (C) is consistent with a glutamine-dependent amidotransferase involved in NAD+ biosynthesis. No other option is defensible."
  },
  "important_caveats": [
    "The UniProt pathway annotation is based on HAMAP-Rule MF_02090 (ECO:0000255), a computational/curated assignment, not direct enzymatic assay evidence for this specific protein. However, a 2024 disruption phenotype study (PubMed 38429435) provides experimental support for NAD+ biosynthesis function in this organism.",
    "The reviewer identified the accession from dataset metadata; the evaluated model received only the raw sequence and four pathway labels.",
    "The pathway annotation is a broad category ('Cofactor biosynthesis'); the full UniProt line specifies the sub-pathway 'NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1,' but the question only asks for the top-level pathway."
  ]
}
```

</details>

## After: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence-matched record annotates the protein as glutamine-dependent NAD(+) synthetase and places it in NAD(+) biosynthesis, a cofactor biosynthesis pathway. The annotations are attributed to a HAMAP rule, so this is computational support rather than direct experimental evidence in the supplied excerpts.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The 552-residue sequence is consistent with the two-domain glutamine-dependent NAD synthetase family: an N-terminal glutamine-hydrolyzing domain coupled to a C-terminal nucleotide-synthetase domain. Family knowledge links this enzyme to NAD biosynthesis, which meaningfully selects cofactor biosynthesis (C) over cystathionine formation, antifungal biosynthesis, or membrane lipid metabolism.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> The sequence and transferable knowledge of NAD synthetase family architecture and function provide a credible pathway-level inference without needing this exact protein's database record.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The choices distinguish NAD/cofactor biosynthesis from unrelated pathways; the sequence-supported enzyme-family inference favors C.


### Important caveats

- The supplied pathway annotation is computational (HAMAP-rule evidence); the excerpts do not independently establish experimental validation.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The 552-residue sequence is consistent with the two-domain glutamine-dependent NAD synthetase family: an N-terminal glutamine-hydrolyzing domain coupled to a C-terminal nucleotide-synthetase domain. Family knowledge links this enzyme to NAD biosynthesis, which meaningfully selects cofactor biosynthesis (C) over cystathionine formation, antifungal biosynthesis, or membrane lipid metabolism.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "The sequence and transferable knowledge of NAD synthetase family architecture and function provide a credible pathway-level inference without needing this exact protein's database record."
  },
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5"
    ],
    "judgment": "supported",
    "reason": "The sequence-matched record annotates the protein as glutamine-dependent NAD(+) synthetase and places it in NAD(+) biosynthesis, a cofactor biosynthesis pathway. The annotations are attributed to a HAMAP rule, so this is computational support rather than direct experimental evidence in the supplied excerpts."
  },
  "important_caveats": [
    "The supplied pathway annotation is computational (HAMAP-rule evidence); the excerpts do not independently establish experimental validation."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The choices distinguish NAD/cofactor biosynthesis from unrelated pathways; the sequence-supported enzyme-family inference favors C."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence-matched record annotates the protein as glutamine-dependent NAD(+) synthetase and places it in NAD(+) biosynthesis, a cofactor biosynthesis pathway. The annotations are attributed to a HAMAP rule, so this is computational support rather than direct experimental evidence in the supplied excerpts.",
    "evidence_ids": ["C4", "C5"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The 552-residue sequence is consistent with the two-domain glutamine-dependent NAD synthetase family: an N-terminal glutamine-hydrolyzing domain coupled to a C-terminal nucleotide-synthetase domain. Family knowledge links this enzyme to NAD biosynthesis, which meaningfully selects cofactor biosynthesis (C) over cystathionine formation, antifungal biosynthesis, or membrane lipid metabolism.",
    "missing_item_specific_fact": "",
    "reason": "The sequence and transferable knowledge of NAD synthetase family architecture and function provide a credible pathway-level inference without needing this exact protein's database record."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The choices distinguish NAD/cofactor biosynthesis from unrelated pathways; the sequence-supported enzyme-family inference favors C."
  },
  "important_caveats": [
    "The supplied pathway annotation is computational (HAMAP-rule evidence); the excerpts do not independently establish experimental validation."
  ]
}
```

</details>

## After: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt annotation (evidence C5, H3) explicitly assigns the pathway as 'Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1' under HAMAP-Rule MF_02090 (ECO:0000255, computational/family-based). A 2024 PubMed reference (38429435, C6/H2) provides structural and disruption-phenotype evidence for NAD+ biosynthesis in Xanthomonas campestris pv. campestris. The expected answer 'Cofactor biosynthesis' matches the top-level UniProt pathway category. The annotation is primarily family-based (HAMAP), but corroborated by experimental structural work.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: reasoning-supported

**Discriminating biological argument**

> The sequence contains the highly diagnostic GIDSA motif (residues ~'GIDSALVLAMAVDALGGEN') and the catalytic Cys of a Cys-His-Glu triad in 'GDMCGGY', which are hallmark features of the glutamine amidotransferase (GAT) domain family. This is a well-known, transferable sequence signature learned from many GAT enzymes (e.g., GMP synthase, carbamoyl phosphate synthetase, phosphoribosyl-ATP pyrophosphohydrolase). The overall two-domain architecture (N-terminal synthetase/adenylase domain + C-terminal GAT domain, ~550 aa total) is characteristic of glutamine-dependent synthetases that transfer an amide nitrogen. Among the four options: (B) cystathionine gamma-synthase is a PLP-dependent enzyme with entirely different sequence features and would not contain a GIDSA/GAT motif; (D) membrane lipid metabolism enzymes (e.g., desaturases, acyltransferases) do not typically harbor GAT domains; (A) antifungal biosynthesis is not a standard UniProt pathway category and does not match GAT-domain enzymes. Cofactor biosynthesis (C) is the natural fit: NAD+ is a classic redox cofactor, and the GAT domain is prevalent in cofactor/nucleotide biosynthesis enzymes (GMP synthase, NAD+ synthetase, FAD synthetase). Thus, recognizing the GIDSA/GAT signature and the synthetase+GAT architecture from the raw sequence, combined with the well-established pattern that GAT domains cluster in cofactor biosynthesis, meaningfully distinguishes C from the other three options.


**Missing item-specific fact**

Empty string, as saved.


**Reason**

> The GIDSA motif and Cys-His-Glu triad are directly readable from the supplied sequence and are textbook GAT-domain signatures. The association of GAT-containing synthetases with cofactor biosynthesis is a broad, transferable biochemical pattern. The distractors (PLP-dependent cystathionine synthase, membrane lipid enzymes, antifungal biosynthesis) are inconsistent with a GAT-domain architecture, making C the most defensible choice without needing the exact UniProt annotation for this protein.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The GAT domain signature and synthetase architecture clearly point to cofactor biosynthesis (C). Option B (cystathionine gamma-synthase) is a PLP enzyme with no GAT domain; D (membrane lipid metabolism) lacks GAT involvement; A (antifungal biosynthesis) is not a standard pathway category and does not match the domain architecture. No two options are genuinely defensible given the sequence features.


### Important caveats

- The primary UniProt pathway annotation is HAMAP-rule-based (ECO:0000255), i.e., a protein-family computational assignment rather than direct enzymatic assay. However, a 2024 structural and disruption-phenotype study (PubMed:38429435) provides experimental corroboration for NAD+ biosynthesis in this organism.
- The option text 'Cofactor biosynthesis' is the broad UniProt top-level pathway category; the full annotation specifies NAD(+) biosynthesis as a sub-pathway. This is consistent and not ambiguous.
- The GIDSA motif is a strong but not absolutely unique GAT signature; however, combined with the full domain architecture and the elimination of clearly incompatible distractors, it provides a robust and transferable basis for selecting C.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains the highly diagnostic GIDSA motif (residues ~'GIDSALVLAMAVDALGGEN') and the catalytic Cys of a Cys-His-Glu triad in 'GDMCGGY', which are hallmark features of the glutamine amidotransferase (GAT) domain family. This is a well-known, transferable sequence signature learned from many GAT enzymes (e.g., GMP synthase, carbamoyl phosphate synthetase, phosphoribosyl-ATP pyrophosphohydrolase). The overall two-domain architecture (N-terminal synthetase/adenylase domain + C-terminal GAT domain, ~550 aa total) is characteristic of glutamine-dependent synthetases that transfer an amide nitrogen. Among the four options: (B) cystathionine gamma-synthase is a PLP-dependent enzyme with entirely different sequence features and would not contain a GIDSA/GAT motif; (D) membrane lipid metabolism enzymes (e.g., desaturases, acyltransferases) do not typically harbor GAT domains; (A) antifungal biosynthesis is not a standard UniProt pathway category and does not match GAT-domain enzymes. Cofactor biosynthesis (C) is the natural fit: NAD+ is a classic redox cofactor, and the GAT domain is prevalent in cofactor/nucleotide biosynthesis enzymes (GMP synthase, NAD+ synthetase, FAD synthetase). Thus, recognizing the GIDSA/GAT signature and the synthetase+GAT architecture from the raw sequence, combined with the well-established pattern that GAT domains cluster in cofactor biosynthesis, meaningfully distinguishes C from the other three options.",
    "judgment": "reasoning_supported",
    "missing_item_specific_fact": "",
    "reason": "The GIDSA motif and Cys-His-Glu triad are directly readable from the supplied sequence and are textbook GAT-domain signatures. The association of GAT-containing synthetases with cofactor biosynthesis is a broad, transferable biochemical pattern. The distractors (PLP-dependent cystathionine synthase, membrane lipid enzymes, antifungal biosynthesis) are inconsistent with a GAT-domain architecture, making C the most defensible choice without needing the exact UniProt annotation for this protein."
  },
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt annotation (evidence C5, H3) explicitly assigns the pathway as 'Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1' under HAMAP-Rule MF_02090 (ECO:0000255, computational/family-based). A 2024 PubMed reference (38429435, C6/H2) provides structural and disruption-phenotype evidence for NAD+ biosynthesis in Xanthomonas campestris pv. campestris. The expected answer 'Cofactor biosynthesis' matches the top-level UniProt pathway category. The annotation is primarily family-based (HAMAP), but corroborated by experimental structural work."
  },
  "important_caveats": [
    "The primary UniProt pathway annotation is HAMAP-rule-based (ECO:0000255), i.e., a protein-family computational assignment rather than direct enzymatic assay. However, a 2024 structural and disruption-phenotype study (PubMed:38429435) provides experimental corroboration for NAD+ biosynthesis in this organism.",
    "The option text 'Cofactor biosynthesis' is the broad UniProt top-level pathway category; the full annotation specifies NAD(+) biosynthesis as a sub-pathway. This is consistent and not ambiguous.",
    "The GIDSA motif is a strong but not absolutely unique GAT signature; however, combined with the full domain architecture and the elimination of clearly incompatible distractors, it provides a robust and transferable basis for selecting C."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The GAT domain signature and synthetase architecture clearly point to cofactor biosynthesis (C). Option B (cystathionine gamma-synthase) is a PLP enzyme with no GAT domain; D (membrane lipid metabolism) lacks GAT involvement; A (antifungal biosynthesis) is not a standard pathway category and does not match the domain architecture. No two options are genuinely defensible given the sequence features."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0051",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt annotation (evidence C5, H3) explicitly assigns the pathway as 'Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1' under HAMAP-Rule MF_02090 (ECO:0000255, computational/family-based). A 2024 PubMed reference (38429435, C6/H2) provides structural and disruption-phenotype evidence for NAD+ biosynthesis in Xanthomonas campestris pv. campestris. The expected answer 'Cofactor biosynthesis' matches the top-level UniProt pathway category. The annotation is primarily family-based (HAMAP), but corroborated by experimental structural work.",
    "evidence_ids": ["C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "reasoning_supported",
    "discriminating_biological_argument": "The sequence contains the highly diagnostic GIDSA motif (residues ~'GIDSALVLAMAVDALGGEN') and the catalytic Cys of a Cys-His-Glu triad in 'GDMCGGY', which are hallmark features of the glutamine amidotransferase (GAT) domain family. This is a well-known, transferable sequence signature learned from many GAT enzymes (e.g., GMP synthase, carbamoyl phosphate synthetase, phosphoribosyl-ATP pyrophosphohydrolase). The overall two-domain architecture (N-terminal synthetase/adenylase domain + C-terminal GAT domain, ~550 aa total) is characteristic of glutamine-dependent synthetases that transfer an amide nitrogen. Among the four options: (B) cystathionine gamma-synthase is a PLP-dependent enzyme with entirely different sequence features and would not contain a GIDSA/GAT motif; (D) membrane lipid metabolism enzymes (e.g., desaturases, acyltransferases) do not typically harbor GAT domains; (A) antifungal biosynthesis is not a standard UniProt pathway category and does not match GAT-domain enzymes. Cofactor biosynthesis (C) is the natural fit: NAD+ is a classic redox cofactor, and the GAT domain is prevalent in cofactor/nucleotide biosynthesis enzymes (GMP synthase, NAD+ synthetase, FAD synthetase). Thus, recognizing the GIDSA/GAT signature and the synthetase+GAT architecture from the raw sequence, combined with the well-established pattern that GAT domains cluster in cofactor biosynthesis, meaningfully distinguishes C from the other three options.",
    "missing_item_specific_fact": "",
    "reason": "The GIDSA motif and Cys-His-Glu triad are directly readable from the supplied sequence and are textbook GAT-domain signatures. The association of GAT-containing synthetases with cofactor biosynthesis is a broad, transferable biochemical pattern. The distractors (PLP-dependent cystathionine synthase, membrane lipid enzymes, antifungal biosynthesis) are inconsistent with a GAT-domain architecture, making C the most defensible choice without needing the exact UniProt annotation for this protein."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The GAT domain signature and synthetase architecture clearly point to cofactor biosynthesis (C). Option B (cystathionine gamma-synthase) is a PLP enzyme with no GAT domain; D (membrane lipid metabolism) lacks GAT involvement; A (antifungal biosynthesis) is not a standard pathway category and does not match the domain architecture. No two options are genuinely defensible given the sequence features."
  },
  "important_caveats": [
    "The primary UniProt pathway annotation is HAMAP-rule-based (ECO:0000255), i.e., a protein-family computational assignment rather than direct enzymatic assay. However, a 2024 structural and disruption-phenotype study (PubMed:38429435) provides experimental corroboration for NAD+ biosynthesis in this organism.",
    "The option text 'Cofactor biosynthesis' is the broad UniProt top-level pathway category; the full annotation specifies NAD(+) biosynthesis as a sub-pathway. This is consistent and not ambiguous.",
    "The GIDSA motif is a strong but not absolutely unique GAT signature; however, combined with the full domain architecture and the elimination of clearly incompatible distractors, it provides a robust and transferable basis for selecting C."
  ]
}
```

</details>

## Existing project source checks of the old Luna review only

These unchanged notes concern the earlier Luna claims. They do not validate either new review or the old Qwen review. No new scientific adjudication was performed.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Complete reviewer-only evidence and qualifications

All excerpts supplied in the original and revised reviewer user message follow. This material was not available to the original evaluated model. Accession identity came from dataset image-path metadata. Source support and transferable discrimination are separate judgments.

**Applicability metadata, unchanged:**

```json
{
  "requested_accession": "A0A0H2X6L3",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "benchmark_sequence_sha256": "3d11eda2e9e6481a31767f7fc550e14d13db9c3ed7ac21360bb4b2288341703d",
  "benchmark_sequence_length": 552,
  "current_status": "retrieved",
  "current_sequence_comparison": "matched",
  "current_entry_audit": {
    "entryVersion": 50,
    "firstPublicDate": "2025-02-05",
    "lastAnnotationUpdateDate": "2026-06-10",
    "lastSequenceUpdateDate": "2015-09-16",
    "sequenceVersion": 1
  },
  "current_uniprot_release": "2026_03",
  "current_record_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "current_source_sequence_sha256": "3d11eda2e9e6481a31767f7fc550e14d13db9c3ed7ac21360bb4b2288341703d",
  "current_source_sequence_length": 552,
  "historical_status": "retrieved",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "selected_historical_entry_version": 49,
  "selected_historical_version": {
    "accession": "A0A0H2X6L3",
    "database": "Swiss-Prot",
    "entryVersion": 49,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_01/2026_01",
    "lastReleaseDate": "28-Jan-2026",
    "name": "NADE_XANC8",
    "sequenceVersion": 1
  },
  "selected_historical_record_sha256": "fb3a35bb9946c1cd8f5bc8cbdbcf89a05f7652dac19292f276cf608a43a2cb41",
  "selected_historical_source_sequence_sha256": "3d11eda2e9e6481a31767f7fc550e14d13db9c3ed7ac21360bb4b2288341703d",
  "selected_historical_source_sequence_length": 552,
  "latest_at_cutoff_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 49,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "actual_author_source_snapshot": "unknown",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed."
}
```

**Qualifications, unchanged:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json)

```json
{
  "evidence_id": "C1",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json",
  "source_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "retrieved_utc": "2026-11-02T04:24:06.673007+00:00",
  "json_pointer": "/primaryAccession",
  "excerpt": "\"A0A0H2X6L3\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json)

```json
{
  "evidence_id": "C2",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json",
  "source_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "retrieved_utc": "2026-11-02T04:24:06.673007+00:00",
  "json_pointer": "/entryAudit",
  "excerpt": "{\"entryVersion\":50,\"firstPublicDate\":\"2025-02-05\",\"lastAnnotationUpdateDate\":\"2026-06-10\",\"lastSequenceUpdateDate\":\"2015-09-16\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json)

```json
{
  "evidence_id": "C3",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json",
  "source_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "retrieved_utc": "2026-11-02T04:24:06.673007+00:00",
  "json_pointer": "/organism",
  "excerpt": "{\"lineage\":[\"Bacteria\",\"Pseudomonadati\",\"Pseudomonadota\",\"Gammaproteobacteria\",\"Lysobacterales\",\"Lysobacteraceae\",\"Xanthomonas\"],\"scientificName\":\"Xanthomonas campestris pv. campestris (strain 8004)\",\"taxonId\":314565}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json)

```json
{
  "evidence_id": "C4",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json",
  "source_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "retrieved_utc": "2026-11-02T04:24:06.673007+00:00",
  "json_pointer": "/proteinDescription",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000255\",\"id\":\"MF_02090\",\"source\":\"HAMAP-Rule\"}],\"value\":\"NAD(+) synthase [glutamine-hydrolyzing]\"}},{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"38429435\",\"source\":\"PubMed\"}],\"value\":\"NAD(+) synthetase\"},\"shortNames\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"38429435\",\"source\":\"PubMed\"}],\"value\":\"NADS\"}]}],\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000255\",\"id\":\"MF_02090\",\"source\":\"HAMAP-Rule\"}],\"value\":\"6.3.5.1\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000255\",\"id\":\"MF_02090\",\"source\":\"HAMAP-Rule\"}],\"value\":\"Glutamine-dependent NAD(+) synthetase\"}}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json)

```json
{
  "evidence_id": "C5",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json",
  "source_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "retrieved_utc": "2026-11-02T04:24:06.673007+00:00",
  "json_pointer": "/comments/2",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000255\",\"id\":\"MF_02090\",\"source\":\"HAMAP-Rule\"}],\"value\":\"Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json)

```json
{
  "evidence_id": "C6",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0H2X6L3.json",
  "source_sha256": "c621b7373f2a6fa91b908243cb91d5f7c41394ff382a16440790296873fffe79",
  "retrieved_utc": "2026-11-02T04:24:06.673007+00:00",
  "json_pointer": "/references/1",
  "excerpt": "{\"citation\":{\"authors\":[\"Xu G.\",\"Ma J.\",\"Fang Q.\",\"Peng Q.\",\"Jiao X.\",\"Hu W.\",\"Zhao Q.\",\"Kong Y.\",\"Liu F.\",\"Shi X.\",\"Tang D.J.\",\"Tang J.L.\",\"Ming Z.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"38429435\"},{\"database\":\"DOI\",\"id\":\"10.1038/s42003-024-05921-3\"}],\"citationType\":\"journal article\",\"firstPage\":\"255\",\"id\":\"38429435\",\"journal\":\"Commun. Biol.\",\"lastPage\":\"255\",\"publicationDate\":\"2024\",\"title\":\"Structural insights into Xanthomonas campestris pv. campestris NAD+ biosynthesis via the NAM salvage pathway.\",\"volume\":\"7\"},\"referenceComments\":[{\"type\":\"STRAIN\",\"value\":\"8004\"}],\"referenceNumber\":2,\"referencePositions\":[\"DISRUPTION PHENOTYPE\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0H2X6L3?format=txt&versions=49)

```json
{
  "evidence_id": "H1",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0H2X6L3?format=txt&versions=49",
  "source_sha256": "fb3a35bb9946c1cd8f5bc8cbdbcf89a05f7652dac19292f276cf608a43a2cb41",
  "retrieved_utc": "2026-11-02T04:24:10.555808+00:00",
  "source_locator": "lines 1-16",
  "excerpt": "ID   NADE_XANC8              Reviewed;         552 AA.\nAC   A0A0H2X6L3;\nDT   05-FEB-2025, integrated into UniProtKB/Swiss-Prot.\nDT   16-SEP-2015, sequence version 1.\nDT   28-JAN-2026, entry version 49.\nDE   RecName: Full=Glutamine-dependent NAD(+) synthetase {ECO:0000255|HAMAP-Rule:MF_02090};\nDE            EC=6.3.5.1 {ECO:0000255|HAMAP-Rule:MF_02090};\nDE   AltName: Full=NAD(+) synthase [glutamine-hydrolyzing] {ECO:0000255|HAMAP-Rule:MF_02090};\nDE   AltName: Full=NAD(+) synthetase {ECO:0000303|PubMed:38429435};\nDE            Short=NADS {ECO:0000303|PubMed:38429435};\nGN   Name=nadE {ECO:0000255|HAMAP-Rule:MF_02090};\nGN   OrderedLocusNames=XC_1067 {ECO:0000312|EMBL:AAY48137.1};\nOS   Xanthomonas campestris pv. campestris (strain 8004).\nOC   Bacteria; Pseudomonadati; Pseudomonadota; Gammaproteobacteria;\nOC   Lysobacterales; Lysobacteraceae; Xanthomonas.\nOX   NCBI_TaxID=314565;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 49,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0H2X6L3?format=txt&versions=49)

```json
{
  "evidence_id": "H2",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0H2X6L3?format=txt&versions=49",
  "source_sha256": "fb3a35bb9946c1cd8f5bc8cbdbcf89a05f7652dac19292f276cf608a43a2cb41",
  "retrieved_utc": "2026-11-02T04:24:10.555808+00:00",
  "source_locator": "lines 28-36",
  "excerpt": "RN   [2]\nRP   DISRUPTION PHENOTYPE.\nRC   STRAIN=8004;\nRX   PubMed=38429435; DOI=10.1038/s42003-024-05921-3;\nRA   Xu G., Ma J., Fang Q., Peng Q., Jiao X., Hu W., Zhao Q., Kong Y., Liu F.,\nRA   Shi X., Tang D.J., Tang J.L., Ming Z.;\nRT   \"Structural insights into Xanthomonas campestris pv. campestris NAD+\nRT   biosynthesis via the NAM salvage pathway.\";\nRL   Commun. Biol. 7:255-255(2024).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 49,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0H2X6L3?format=txt&versions=49)

```json
{
  "evidence_id": "H3",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0H2X6L3?format=txt&versions=49",
  "source_sha256": "fb3a35bb9946c1cd8f5bc8cbdbcf89a05f7652dac19292f276cf608a43a2cb41",
  "retrieved_utc": "2026-11-02T04:24:10.555808+00:00",
  "source_locator": "lines 47-49",
  "excerpt": "CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from\nCC       deamido-NAD(+) (L-Gln route): step 1/1. {ECO:0000255|HAMAP-\nCC       Rule:MF_02090}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 49,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 51. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
